AstraZeneca objected to the second judgment of Forxiga

The company issued a separate statement saying, "We are sorry for the trial decision in the patent court related to material patents"

Forxiga

AstraZeneca lost the second trial of Forxiga's material patent.

 

And AstraZeneca announced that it would appeal to the Supreme Court.

 

AstraZeneca said in a separate statement on the 30th that it disobeyed the judgment of the Patent Court of Korea on the 29th.

 

The Patent Court of Korea sided with 19 companies including Kukje Pharma in a lawsuit related to Forxiga substance patents on the 29th.

 

AstraZeneca said that the criteria for judging the progressiveness of optional inventions are too strict in Korea.

 

AstraZeneca argues that the criteria for judging the progressiveness of optional inventions currently applied by the courts were established by the Supreme Court rulings in the late 1990s and early 2000s, and that the criteria do not meet international standards.

 

AstraZeneca said, "There is a possibility that Eliquis' substance patent, which is pending in the Supreme Court, has recently been referred to the entire consensus, and a new standard for judging the progressiveness of the optional invention is proposed." It criticized, "Even so, we are sorry for the patent court ruling that was made without confirming this case." AstraZeneca said, "No one will be willing to invest in the Korean pharmaceutical industry unless the protection of substance patents is faithfully implemented in Korea." And it also stressed, "We hope that excellent patents in the pharmaceutical field will receive reasonable protection." There are a total of two Forxiga material patents.

 

One expires on April 7, 2023, and the other expires on January 8, 2024.

 

The ruling, which was won by 19 generic companies, concerns a patent that expires in 2024.

 

In the case of the patent expiring in 2023, Dong-A ST is the only one who won the first trial with the “Pro-drug” strategy.